Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-01)

Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study ID
NCT05224934
Status
Recruiting
Apply to this trial

Conditions

  • Radiotherapy Side Effect
  • Retroperitoneal Sarcoma
  • Soft Tissue Sarcoma
  • Stereotactic Ablative Radiotherapy
  • Ultra-hypofractionated Radiotherapy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ultra-hypofractionated radiotherapy — RADIATION
    stereotactic ablative radiotherapy with 25 to 50Gy in five fractions given preoperatively

Study Details

To investigate the feasibility and peri-operative complications of preoperative hypo-fractionated radiotherapy followed by surgery for retroperitoneal sarcoma

Key Dates

First listed
Feb 4, 2022
Start date
Jan 1, 2022
Status verified
Dec 2025
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ultra-hypofractionated radiotherapy
    Patients receive ultra-hypo-fractionated radiotherapy with 25Gy to 50Gy in five fractions, followed by surgery done at 1 to 2 months post-RT

Primary Outcome Measure

Peri-operative complications [ Time Frame: From surgery date up to 7 days later ]

Central Contacts

Related Studies